Abstract:Abstract Background: Type 2 diabetes mellitus (T2DM) is associated with cardiovascular disease (CVD). Sodium glucose cotransporter 2 inhibitors (SGLT2i) represent the most effective oral drugs for the treatment of T2DM, and have been shown to improve generalized vascular dysfunction. However, it’s effect on improving diabetic CVD and the possible action mechanism are currently unclear. Methods: T2DM was induced by feeding a high-fat diet (HFD) to male C57BL/6J mice for 24 weeks. Afterthat, HFD-fed mice were treated with Cana (50 mg/kg/d) or positive drug metformin (225 mg/kg/d) by oral gavage for 6 weeks. Myocardial mitochondrial morphology and cardiovascular abnormalities were assessed by transmission electron microscope and histological staining; lipids profile and oxidative stress state were assessed by corresponding biochemical assay kits and histological staining; myocardial injury was characterized by H&E staining, TUNEL, and ELISA assays; colonic gut microbiota was assessed by 16S rDNA high-throughput sequencing. Results: Cana reduced the lipid (such as TG, TC, and LDL-C) accumulation in serum, thus decreased atherogenic index of plasma and arteriosclerosis index values. And, Cana reduced the circulating markers of inflammation (such as TNFα, MCP-1, and IL-6). More importantly, Cana improved cardiac mitochondrial homeostasis and relieved oxidative stress. Myocardial injury was alleviated after Cana treatment with decreasing levels of serous cTn I and sCD40L. Thus, cardiovascular abnormality was relieved by elevating the CD31 expression level, and suppressing fibrosis and basement membrane thickening in T2DM mice. Interestingly, Cana administration increased the ratio of Firmicutes/Bacteroidetes and the relative abundance of Olsenella , Alistipes , and Alloprevotella , while decreased the abundance of Proteobacteria, Helicobacter and Mucispirillum at various taxonomic levels. Conclusions: Cana treatment improved CVD by decreasing the risk of atherosclerosis, maintaining a relatively normal haemogram, and reducing the thickness of vascular basement membrane and myocardial injury. Importantly, Cana treatment significantly elevated myocardial mitochondria homeostasis, thus ameliorated the oxidative stress and inflammatory states. Moreover, Cana subtly altered microbiota composition in T2DM mice with CVD, which contributed to the improvement of CVD. Collectively, the improvements of myocardial mitochondrial and gut microbiota homeostasis, may represent an important mechanism underlying the cardiovascular benefits of Cana treatment.

Canagliflozin Ameliorates Epithelial-Mesenchymal Transition in High-Salt Diet-Induced Hypertensive Renal Injury Through Restoration of Sirtuin 3 Expression and the Reduction of Oxidative Stress

An Effective Sodium-Dependent Glucose Transporter 2 Inhibition, Canagliflozin, Prevents Development of Hypertensive Heart Failure in Dahl Salt-Sensitive Rats

Canagliflozin Ameliorates Ventricular Remodeling through Apelin/Angiotensin-Converting Enzyme 2 Signaling in Heart Failure with Preserved Ejection Fraction Rats

Sodium-glucose exchanger 2 inhibitor canagliflozin promotes mitochondrial metabolism and alleviates salt-induced cardiac hypertrophy via preserving SIRT3 expression

Suppression of Endothelial-to-Mesenchymal Transition by SIRT (sirtuin) 3 Alleviated the Development of Hypertensive Renal Injury

S-18-3: SGLT2 INHIBITOR CANAGLIFLOZIN ANTAGONIZES SALT-SENSITIVE HYPERTENSION THROUGH MODIFYING TRPC3 MEDIATED VASCULAR CALCIUM HANDLING

A8324 Suppression of Endothelial to Mesenchymal Transition by SIRT3 Alleviated the Development of Hypertensive Renal Injury

Canagliflozin inhibits PASMCs proliferation via regulating SGLT1/AMPK signaling and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension

C-atrial natriuretic peptide (ANP)4-23 attenuates renal fibrosis in deoxycorticosterone-acetate-salt hypertensive mice

Canagliflozin Alleviates Atherosclerosis Progression Through Inflammation, Oxidative Stress, and Autophagy in Western Diet-fed ApoE −/− Mice

Canagliflozin alleviates high glucose-induced peritoneal fibrosis via HIF-1α inhibition

Canagliflozin ameliorates high glucose-induced apoptosis in NRK-52E cells via inhibiting oxidative stress and activating AMPK/mTOR-mediated autophagy

Canagliflozin Mediates Mitophagy Through the AMPK/PINK1/Parkin Pathway to Alleviate ISO-induced Cardiac Remodeling.

SIRT3-KLF15 Signaling Ameliorates Kidney Injury Induced by Hypertension.

Canagliflozin mediates mitophagy through the AMPK/PINK1/PARKIN pathway to alleviate isoprenaline-induced cardiac remodelling

Sodium‐Glucose Cotransporter‐2 Inhibitor Suppresses Endoplasmic Reticulum Stress and Oxidative Stress in Diabetic Nephropathy Through Nrf2 Signaling: A Clinical and Experimental Study

Canagliflozin Alleviates Diabetic Cardiovascular Disease via Lipid Lowering, Mitochondrial Homeostasis, and Gut Microbiota Regulation

Canagliflozin Attenuates Lipotoxicity in Cardiomyocytes and Protects Diabetic Mouse Hearts by Inhibiting the Mtor/hif-1Α Pathway

Canagliflozin Attenuates Lipotoxicity in Cardiomyocytes and Protects Diabetic Mouse Hearts by Targeting the mTOR/HIF-1α Pathway

Canagliflozin Ameliorates the Development of NAFLD by Preventing NLRP3-mediated Pyroptosis Through FGF21-ERK1/2 Pathway

Calcitriol ameliorates renal injury with high-salt diet-induced hypertension by upregulating GLIS2 expression and AMPK/mTOR-regulated autophagy